Caredx innovation showcased in record-breaking number of scientific abstracts with over 50 presented at 2022 transplant congress

South san francisco, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2022 american transplant congress (atc) with over 50 oral and scientific poster presentations. caredx will also be sponsoring a symposium, three product theatres, and an innovation day session
CDNA Ratings Summary
CDNA Quant Ranking